Table 4.

Analysis of variance of KDQofL-SF scores and Hgb levels^a

Instrument/Parameter	Hgb				P
	<11	11-<12	12-<13	>13	Hgb	Hgb-Epoetin Interaction
KDQOL
kidney disease component summary	73.8	74.9	73.3	75.1	0.503	0.407
symptom problem	78.6	79.2	78.3	82.7	0.018	0.802
effects kidney disease	82.6	82.0	80.8	84.4	0.217	0.896
burden kidney disease	70.9	75.2	70.1	69.7	0.097	0.604
work status	43.0	43.2	46.8	46.8	0.517	0.584
cognitive function	84.9	83.9	83.0	83.8	0.786	0.959
quality social interaction	80.8	83.6	79.9	79.9	0.074	0.587
sexual function	83.2	85.4	77.9	85.4	0.321	0.500
sleep	65.3	65.2	61.7	67.2	0.070	0.097
social support	83.7	83.1	82.8	83.5	0.980	0.842
SF-36
mental component summary	49.7	50.5	50.0	49.5	0.820	0.979
physical component summary	37.4	39.9	38.5	41.0	0.008	0.333
physical functioning	51.2	56.9	53.1	60.7	0.003	0.920
role—physical	40.8	51.7	47.1	56.9	0.002	0.275
pain	67.4	71.4	63.7	70.8	0.015	0.694
general health	44.9	47.0	45.9	50.4	0.049	0.403
emotional well being	73.0	76.3	73.9	73.2	0.285	0.634
role—emotional	68.5	73.4	68.2	75.6	0.182	0.326
social function	71.7	76.9	72.8	76.2	0.152	0.434
energy/fatigue	43.4	48.8	49.0	50.1	0.024	0.213

^aAdjusted for age, CKD stage, and albumin level; presence or absence of a history of diabetes, congestive heart failure, or myocardial infarction; the use of erythropoietin-stimulating agents (ESA) or supplemental iron (oral or intravenous); and the interaction of Hgb level and ESA.